Zai Historical Balance Sheet
ZLAB Stock | USD 28.87 0.74 2.63% |
Trend analysis of Zai Lab balance sheet accounts such as Total Assets of 754.6 M, Other Current Liab of 61.8 M, Total Current Liabilities of 213.2 M or Total Stockholder Equity of 623.6 M provides information on Zai Lab's total assets, liabilities, and equity, which is the actual value of Zai Lab to its prevalent stockholders. By breaking down trends over time using Zai Lab balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Zai Lab latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Zai Lab is a good buy for the upcoming year.
Zai Lab Inventory |
|
Zai |
About Zai Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Zai Lab at a specified time, usually calculated after every quarter, six months, or one year. Zai Lab Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Zai Lab and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Zai currently owns. An asset can also be divided into two categories, current and non-current.
Zai Lab Balance Sheet Chart
Add Fundamental
Total Current Liabilities
Total Current Liabilities is an item on Zai Lab balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Zai Lab are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Liabilities And Stockholders Equity
The total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation.Most accounts from Zai Lab's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Zai Lab current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zai Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Zai Stock refer to our How to Trade Zai Stock guide.At present, Zai Lab's Other Current Liabilities is projected to decrease significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 213.2 M, whereas Total Assets are forecasted to decline to about 754.6 M.
2021 | 2022 | 2023 | 2024 (projected) | Cash | 964.1M | 1.0B | 790.2M | 448.6M | Accounts Payable | 126.2M | 66.0M | 113.0M | 118.6M |
Zai Lab balance sheet Correlations
Click cells to compare fundamentals
Zai Lab Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Zai Lab balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 355.2M | 1.3B | 1.6B | 1.2B | 1.0B | 754.6M | |
Other Current Liab | 10.3M | 24.0M | 46.1M | 45.5M | 58.9M | 61.8M | |
Total Current Liabilities | 46.6M | 98.0M | 192.9M | 139.8M | 203.1M | 213.2M | |
Total Stockholder Equity | 294.7M | 1.2B | 1.4B | 1.0B | 796.1M | 623.6M | |
Other Liab | 2.9M | 16.9M | 27.5M | 21.4M | 24.6M | 25.8M | |
Net Tangible Assets | 285.9M | 1.2B | 1.4B | 1.0B | 1.2B | 1.3B | |
Property Plant And Equipment Net | 36.9M | 47.1M | 58.3M | 78.8M | 68.7M | 39.8M | |
Net Debt | (54.2M) | (423.5M) | (948.6M) | (988.1M) | (775M) | (736.3M) | |
Retained Earnings | (444.7M) | (713.6M) | (1.4B) | (1.9B) | (2.2B) | (2.1B) | |
Accounts Payable | 22.7M | 62.6M | 126.2M | 66.0M | 113.0M | 118.6M | |
Cash | 75.9M | 442.1M | 964.1M | 1.0B | 790.2M | 448.6M | |
Non Current Assets Total | 62.7M | 81.6M | 109.1M | 95.8M | 96.7M | 61.5M | |
Cash And Short Term Investments | 275.9M | 1.2B | 1.4B | 1.0B | 806.5M | 644.9M | |
Common Stock Total Equity | 3.0K | 3.5K | 4K | 5K | 5.8K | 3.0K | |
Common Stock Shares Outstanding | 87.8M | 77.7M | 93.0M | 95.8M | 96.6M | 76.3M | |
Liabilities And Stockholders Equity | 355.2M | 1.3B | 1.6B | 1.2B | 1.0B | 754.6M | |
Non Current Liabilities Total | 13.9M | 30.3M | 37.1M | 34.7M | 37.1M | 28.5M | |
Other Current Assets | 6.7M | 10.9M | 18.0M | 35.7M | 23.0M | 12.4M | |
Other Stockholder Equity | 734.7M | 1.9B | 2.8B | 2.9B | 3.0B | 1.5B | |
Total Liab | 60.5M | 128.3M | 230M | 174.5M | 240.2M | 131.0M | |
Total Current Assets | 292.5M | 1.2B | 1.5B | 1.1B | 939.6M | 693.0M | |
Accumulated Other Comprehensive Income | 4.6M | (14.5M) | (23.6M) | 25.7M | 37.6M | 39.5M | |
Intangible Assets | 8.8M | 9.4M | 9.7M | 8.4M | 16.5M | 17.3M | |
Common Stock | 3.5K | 4.1K | 5K | 6K | 6.9K | 4.2K | |
Property Plant Equipment | 36.4M | 46.9M | 57.3M | 77.4M | 89.0M | 93.4M | |
Non Currrent Assets Other | 510.2K | 743K | 803K | 2.2M | 2.3M | 2.4M | |
Other Assets | 15.1M | 110.1M | 26.5M | 3.6M | 4.1M | 3.9M | |
Long Term Investments | 2.4M | 1.3M | 15.6M | 6.4M | 9.2M | 5.5M | |
Current Deferred Revenue | 2.9M | 24.7M | 27.5M | 21.4M | 19.2M | 18.3M | |
Net Invested Capital | 301.1M | 1.2B | 1.4B | 1.0B | 796.1M | 814.3M | |
Net Working Capital | 245.8M | 1.1B | 1.3B | 984.5M | 736.5M | 759.3M | |
Short Term Debt | 10.8M | 10.4M | 11.9M | 7.1M | 14.2M | 13.5M | |
Short Long Term Debt Total | 21.8M | 18.6M | 15.5M | 20.4M | 15.2M | 17.4M | |
Net Receivables | 3.8M | 5.2M | 54.8M | 48.6M | 65.3M | 68.6M | |
Short Term Investments | 200M | 744.7M | 445M | 0.0 | 16.3M | 15.5M | |
Inventory | 6.0M | 13.1M | 19.0M | 31.6M | 44.8M | 47.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zai Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zai Lab's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zai Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zai Lab Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zai Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Zai Stock refer to our How to Trade Zai Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zai Lab. If investors know Zai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zai Lab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.80) | Revenue Per Share 3.647 | Quarterly Revenue Growth 0.477 | Return On Assets (0.21) | Return On Equity (0.35) |
The market value of Zai Lab is measured differently than its book value, which is the value of Zai that is recorded on the company's balance sheet. Investors also form their own opinion of Zai Lab's value that differs from its market value or its book value, called intrinsic value, which is Zai Lab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zai Lab's market value can be influenced by many factors that don't directly affect Zai Lab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zai Lab's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zai Lab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zai Lab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.